Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9  months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in pr...

Source: BMC Medicine - June 22, 2020 Category: Internal Medicine Authors: N. Garc ía-Romero, I. Palacín-Aliana, R. Madurga, J. Carrión-Navarro, S. Esteban-Rubio, B. Jiménez, A. Collazo, F. Pérez-Rodríguez, A. Ortiz de Mendivil, C. Fernández-Carballal, S. García-Duque, J. Diamantopoulos-Fernández, C. Belda-Iniesta, R. P Tags: Research article Source Type: research